{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:26:53Z","timestamp":1792175213541,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cases of myocarditis and pericarditis have been reported following the receipt of Covid-19 mRNA vaccines. As vaccination campaigns are still to be extended, we aimed to provide a comprehensive assessment of the association, by vaccine and across sex and age groups. Using nationwide hospital discharge and vaccine data, we analysed all 1612 cases of myocarditis and 1613 cases of pericarditis that occurred in France in the period from May 12, 2021 to October 31, 2021. We perform matched case-control studies and find increased risks of myocarditis and pericarditis during the first week following vaccination, and particularly after the second dose, with adjusted odds ratios of myocarditis of 8.1 (95% confidence interval [CI], 6.7 to 9.9) for the BNT162b2 and 30 (95% CI, 21 to 43) for the mRNA-1273 vaccine. The largest associations are observed for myocarditis following mRNA-1273 vaccination in persons aged 18 to 24 years. Estimates of excess cases attributable to vaccination also reveal a substantial burden of both myocarditis and pericarditis across other age groups and in both males and females.<\/jats:p>","DOI":"10.1038\/s41467-022-31401-5","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T06:03:19Z","timestamp":1656136999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1303-8281","authenticated-orcid":false,"given":"St\u00e9phane","family":"Le Vu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7946-7759","authenticated-orcid":false,"given":"Marie-Joelle","family":"Jabagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-6370","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Botton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Drouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9rang\u00e8re","family":"Baricault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8687-9092","authenticated-orcid":false,"given":"Alain","family":"Weill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7646-3667","authenticated-orcid":false,"given":"Rosemary","family":"Dray-Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"31401_CR1","unstructured":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3\u20136 May 2021. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021 (2021)."},{"key":"31401_CR2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","volume":"70","author":"JW Gargano","year":"2021","unstructured":"Gargano, J. W. et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices \u2014 United States, June 2021. MMWR Morb. Mortal. Wkly. Rep. 70, 977\u2013982 (2021).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"31401_CR3","unstructured":"Surveillance of Myocarditis (Inflammation of the Heart Muscle) Cases Between December 2020 and May 2021 (Including). https:\/\/www.gov.il\/en\/departments\/news\/01062021-03 (2021)."},{"key":"31401_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.2021.24110","volume":"327","author":"ME Oster","year":"2022","unstructured":"Oster, M. E. et al. Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US From December 2020 to August 2021. JAMA 327, 331\u2013340 (2022).","journal-title":"JAMA"},{"key":"31401_CR5","doi-asserted-by":"publisher","unstructured":"Mevorach, D. et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N. Engl. J. Med. 2140\u20132149 https:\/\/doi.org\/10.1056\/NEJMoa2109730 (2021).","DOI":"10.1056\/NEJMoa2109730"},{"key":"31401_CR6","doi-asserted-by":"publisher","unstructured":"Witberg, G. et al. Myocarditis after Covid-19 vaccination in a Large Health Care Organization. N. Engl. J. Med. 2132\u20132139 https:\/\/doi.org\/10.1056\/NEJMoa2110737 (2021).","DOI":"10.1056\/NEJMoa2110737"},{"key":"31401_CR7","doi-asserted-by":"publisher","unstructured":"Husby, A. et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ e068665 https:\/\/doi.org\/10.1136\/bmj-2021-068665 (2021).","DOI":"10.1136\/bmj-2021-068665"},{"key":"31401_CR8","doi-asserted-by":"publisher","unstructured":"Barda, N. et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N. Engl. J. Med. 1078\u20131090 https:\/\/doi.org\/10.1056\/NEJMoa2110475 (2021).","DOI":"10.1056\/NEJMoa2110475"},{"key":"31401_CR9","doi-asserted-by":"publisher","unstructured":"Lai, F. T. T. et al. Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine. Ann. Intern. Med. https:\/\/doi.org\/10.7326\/M21-3700 (2022).","DOI":"10.7326\/M21-3700"},{"key":"31401_CR10","doi-asserted-by":"publisher","unstructured":"Patone, M. et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat. Med. 1\u201313 https:\/\/doi.org\/10.1038\/s41591-021-01630-0 (2021).","DOI":"10.1038\/s41591-021-01630-0"},{"key":"31401_CR11","unstructured":"EMA. Signal assessment report on Myocarditis, pericarditis with Tozinameran. https:\/\/www.ema.europa.eu\/documents\/prac-recommendation\/signal-assessment-report-myocarditis-pericarditis-tozinameran-covid-19-mrna-vaccine_en.pdf (2021)."},{"key":"31401_CR12","unstructured":"Le tableau de bord de la vaccination. https:\/\/solidarites-sante.gouv.fr\/grands-dossiers\/vaccin-covid-19\/article\/le-tableau-de-bord-de-la-vaccination (2021)."},{"key":"31401_CR13","unstructured":"Enqu\u00eate de pharmacovigilance du vaccin COVID\u201019 VACCINE MODERNA. https:\/\/ansm.sante.fr\/uploads\/2021\/10\/22\/20211021-covid-19-vaccins-moderna-focus-1-2.pdf (2021)."},{"key":"31401_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","volume":"144","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt, B., Kamat, I. & Hotez, P. J. Myocarditis with COVID-19 mRNA vaccines. Circulation 144, 471\u2013484 (2021).","journal-title":"Circulation"},{"key":"31401_CR15","unstructured":"Klein, N. Myocarditis Analyses in the Vaccine Safety Datalink: Rapid Cycle Analyses and \u201cHead-to-Head\u201d Product Comparisons. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-10-20-21\/08-COVID-Klein-508.pdf (2021)."},{"key":"31401_CR16","doi-asserted-by":"publisher","unstructured":"Dagan, N., Barda, N. & Balicer, R. D. Adverse effects after BNT162b2 vaccine and SARS-CoV-2 infection, according to age and sex. N. Engl. J. Med. 2299 https:\/\/doi.org\/10.1056\/NEJMc2115045 (2021).","DOI":"10.1056\/NEJMc2115045"},{"key":"31401_CR17","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","volume":"326","author":"NP Klein","year":"2021","unstructured":"Klein, N. P. et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 326, 1390\u20131399 (2021).","journal-title":"JAMA"},{"key":"31401_CR18","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1001\/jama.2021.13443","volume":"326","author":"GA Diaz","year":"2021","unstructured":"Diaz, G. A. et al. Myocarditis and pericarditis after vaccination for COVID-19. JAMA 326, 1210\u20131212 (2021).","journal-title":"JAMA"},{"key":"31401_CR19","unstructured":"Su, J. R. Myopericarditis following COVID-19 vaccination: Updates from the Vaccine Adverse Event Reporting System (VAERS). https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-10-20-21\/07-COVID-Su-508.pdf (2021)."},{"key":"31401_CR20","doi-asserted-by":"publisher","unstructured":"Lane, S. & Shakir, S. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccines: A review of spontaneously reported data from the UK, Europe, and the US. 2021.09.09.21263342 https:\/\/www.medrxiv.org\/content\/10.1101\/2021.09.09.21263342v1, https:\/\/doi.org\/10.1101\/2021.09.09.21263342 (2021).","DOI":"10.1101\/2021.09.09.21263342"},{"key":"31401_CR21","doi-asserted-by":"publisher","unstructured":"Chua, G. T. et al. Epidemiology of Acute Myocarditis\/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. ciab989. https:\/\/doi.org\/10.1093\/cid\/ciab989 (2021).","DOI":"10.1093\/cid\/ciab989"},{"key":"31401_CR22","doi-asserted-by":"publisher","unstructured":"Mevorach, D. et al. Myocarditis after BNT162b2 vaccination in Israeli adolescents. N. Engl. J. Med. 998\u2013999. https:\/\/doi.org\/10.1056\/NEJMc2116999 (2022).","DOI":"10.1056\/NEJMc2116999"},{"key":"31401_CR23","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1136\/heartjnl-2013-304449","volume":"99","author":"V Kyt\u00f6","year":"2013","unstructured":"Kyt\u00f6, V., Sipil\u00e4, J. & Rautava, P. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood. Heart 99, 1681\u20131684 (2013).","journal-title":"Heart"},{"key":"31401_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cpcardiol.2012.07.003","volume":"38","author":"D Fairweather","year":"2013","unstructured":"Fairweather, D., Cooper, L. T. & Blauwet, L. A. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr. Probl. Cardiol. 38, 7\u201346 (2013).","journal-title":"Curr. Probl. Cardiol."},{"key":"31401_CR25","doi-asserted-by":"publisher","unstructured":"Heymans, S. & Cooper, L. T. Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. Nat. Rev. Cardiol. 1\u20133. https:\/\/doi.org\/10.1038\/s41569-021-00662-w (2021).","DOI":"10.1038\/s41569-021-00662-w"},{"key":"31401_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","volume":"18","author":"C Tsch\u00f6pe","year":"2021","unstructured":"Tsch\u00f6pe, C. et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat. Rev. Cardiol. 18, 169\u2013193 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"31401_CR27","doi-asserted-by":"publisher","first-page":"e0258391","DOI":"10.1371\/journal.pone.0258391","volume":"16","author":"T Launay","year":"2021","unstructured":"Launay, T. et al. Common communicable diseases in the general population in France during the COVID-19 pandemic. PLOS ONE 16, e0258391 (2021).","journal-title":"PLOS ONE"},{"key":"31401_CR28","doi-asserted-by":"publisher","unstructured":"Li, X. et al. Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong. JAMA Pediatr. https:\/\/doi.org\/10.1001\/jamapediatrics.2022.0101 (2022).","DOI":"10.1001\/jamapediatrics.2022.0101"},{"key":"31401_CR29","doi-asserted-by":"publisher","unstructured":"Hern\u00e1n, M. A. Causal analyses of existing databases: no power calculations required. J. Clin. Epidemiol. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.08.028 (2021).","DOI":"10.1016\/j.jclinepi.2021.08.028"},{"key":"31401_CR30","doi-asserted-by":"crossref","unstructured":"Semenzato, L. et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg. Health \u2013 Eur. 8 (2021).","DOI":"10.1016\/j.lanepe.2021.100158"},{"key":"31401_CR31","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin, J. et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol. Drug Saf. 26, 954\u2013962 (2017).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"31401_CR32","doi-asserted-by":"publisher","unstructured":"H\u00e9kimian, G. et al. Diagnostic et prise en charge des myocardites. M\u00e9decine Intensive R\u00e9animation https:\/\/doi.org\/10.1007\/s13546-017-1273-4 (2017).","DOI":"10.1007\/s13546-017-1273-4"},{"key":"31401_CR33","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler, Y. et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 36, 2921\u20132964 (2015).","journal-title":"Eur. Heart J."},{"key":"31401_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-33","volume":"9","author":"G Rey","year":"2009","unstructured":"Rey, G., Jougla, E., Fouillet, A. & H\u00e9mon, D. Ecological association between a deprivation index and mortality in France over the period 1997\u20132001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health 9, 33 (2009).","journal-title":"BMC Public Health"},{"key":"31401_CR35","unstructured":"Rothman, K. J., Greenland, S. & Lash, T. L. Modern Epidemiology. (Lippincott Williams & Wilkins, 2008)."},{"key":"31401_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/oxfordjournals.epirev.a036144","volume":"16","author":"SS Coughlin","year":"1994","unstructured":"Coughlin, S. S., Benichou, J. & Weed, D. L. Attributable risk estimation in case-control studies. Epidemiol. Rev. 16, 51\u201364 (1994).","journal-title":"Epidemiol. Rev."},{"key":"31401_CR37","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/sim.4780060607","volume":"6","author":"S Greenland","year":"1987","unstructured":"Greenland, S. Variance estimators for attributable fraction estimates consistent in both large strata and sparse data. Stat. Med. 6, 701\u2013708 (1987).","journal-title":"Stat. Med."},{"key":"31401_CR38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/01.ede.0000229155.05644.43","volume":"17","author":"K Steenland","year":"2006","unstructured":"Steenland, K. & Armstrong, B. An overview of methods for calculating the burden of disease due to specific risk factors. Epidemiology 17, 512\u2013519 (2006).","journal-title":"Epidemiology"},{"key":"31401_CR39","unstructured":"R Core Team. R: A language and environment for statistical computing. https:\/\/www.R-project.org\/ (2019)."},{"key":"31401_CR40","unstructured":"Therneau, T. A package for survival analysis in R. 96 (2021)."},{"key":"31401_CR41","doi-asserted-by":"publisher","unstructured":"Le Vu, S. myope2. https:\/\/doi.org\/10.5281\/zenodo.6583550.","DOI":"10.5281\/zenodo.6583550"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31401-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:51:48Z","timestamp":1669312308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31401-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["31401"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-31401-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,25]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3633"}}